<html lang="en" class="js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers no-applicationcache svg inlinesvg smil svgclippaths wf-freightsanspro-n3-active wf-freightsanspro-n5-active wf-freightsanspro-n4-active wf-freightsanspro-i5-active wf-freightsanspro-i3-active wf-freightsanspro-i4-active wf-active" style=""><head>
   <meta charset="UTF-8">

   <title> Research | Pipeline</title>

    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="keywords">
    <meta name="description" content="Our pipeline is more than a list of medicines in development. It reflects the work we do here every day to break new ground with science that makes a difference in the lives of patients.">
    <meta name="language" content="en">
    <meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=1.0">

    <meta name="google-site-verification" content="-iHIKjNfM7R9a5XMEdh6nPfsPqP16R5zQj7fA3LZPwE">

<script type="application/ld+json">
      {
      "@context": "http://schema.org/",
      "@type": "Organization",
      "url": "https://www.biogen.com/",
      "logo": "https://www.biogen.com/content/corporate/en_us/_jcr_content/header/logo.img.full.high.jpg/1435178695993.jpg"
      }
    </script>

    

    <meta property="og:url">
	<meta property="og:image" content="https://www.biogen.com/content/dam/corporate/en_us/images/global-elements/logo-biogen.jpg">
  	<meta property="og:image:width" content="100">
    <meta property="og:image:height" content="100">
    
    
    
    <script src="//assets.adobedtm.com/3a6c1f61c9a73daa8c191c83bc1fe1137a5e6aa3/satelliteLib-75125cc64b408976a6b5cf64bfe356a1727f3c8d.js"></script><!-- 
Start of global snippet: Please do not remove
Place this snippet between the <head> and </head> tags on every page of your site.
-->
<!-- Global site tag (gtag.js) - DoubleClick -->
<!-- <script async src="https://www.googletagmanager.com/gtag/js?id=DC-8302445"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'DC-8302445');
</script> -->
<!-- End of global snippet: Please do not remove -->

	
    
    
    <link rel="icon" type="image/vnd.microsoft.icon" href="/etc/designs/dxp/corp/favicon.ico">
    <link rel="shortcut icon" type="image/vnd.microsoft.icon" href="/etc/designs/dxp/corp/favicon.ico">
    
	<link rel="canonical" href="https://www.biogen.com/en_us/pipeline.html">
	
    
    

    
    
<link rel="stylesheet" href="/etc.clientlibs/foundation/clientlibs/main.min.b4994788cf1eaeed300a0aa7af53f3c8.css" type="text/css">
<script src="/etc.clientlibs/clientlibs/granite/jquery.min.js"></script>
<script src="/etc.clientlibs/clientlibs/granite/utils.min.js"></script>
<script src="/etc.clientlibs/clientlibs/granite/jquery/granite.min.js"></script>
<script src="/etc.clientlibs/foundation/clientlibs/jquery.min.js"></script>
<script src="/etc.clientlibs/foundation/clientlibs/shared.min.js"></script>
<script src="/etc.clientlibs/foundation/clientlibs/main.min.js"></script>



    
    
    
    
<meta name="viewport" content="width=device-width, initial-scale=1.0">



    
<link rel="stylesheet" href="/etc/designs/dxp/corp/clientlib/jquery-ui.min.fa1d542e0d7fee7a004e0f073f01de60.css" type="text/css">




    
<link rel="stylesheet" href="/etc/designs/dxp/corp/clientlib/slick.min.a3a10399a3e0c359a40310b91f49e1d2.css" type="text/css">




<!-- desktop.css for IE8 and below removes media queries -->
<!--[if lt IE 9]>
  <link rel="stylesheet" href="/etc/designs/dxp/corp/clientlib/legacy.min.css"/>
  <link rel="stylesheet" href="/etc/designs/dxp/corp/clientlib/ie.min.css"/>
<![endif]-->


<!--[if gt IE 8]><!-->
  
    
<link rel="stylesheet" href="/etc/designs/dxp/corp/clientlib.min.10f3454c86e706b52f34970f2bc8de32.css" type="text/css">



  
    
<link rel="stylesheet" href="/etc/designs/dxp/corp/clientlib/custom.min.4df4611c09c8944c298f4dc62a619b30.css" type="text/css">



<!--<![endif]-->



  
    
<link rel="stylesheet" href="/etc/designs/dxp/corp/clientlibsansprofonts.min.bbb40712b6b49758d5b60e33be7f4c39.css" type="text/css">






    
    
        <link rel="stylesheet" type="text/css" href="/content/dam/corporate/en_us/images/research-pipeline/pipelineStyle.css">
    

		<script>
			var whitelist = [];
			var graylist = [];
			var blacklist = [];
			var alternativelist = [];
			var internallist = [];
			var abbvielist = [];
			var zinbrytaremslist = [];
			var abovemslist = [];
			var zinbrytahcplist = [];
			var biogenoptionslist = [];
		</script>
		
			
		

        

				
			
			
		
		
		
		
		<script type="text/javascript">
			whitelist.push("biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("clinicalresearch.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("grantsoffice.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("investors.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("jobs.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("media.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("medicalresearch.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("medinfo.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("newsroom.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("abovems.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("avonex.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("msblueprint.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("plegridy.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("plegridyhcp.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("stratifyjcv.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("tecfidera.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("tecfiderahcp.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("togetherinsma.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("tysabri.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("tysabrihcp.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("zinbryta.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen\u002Dinternational.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.at");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.at");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.com.br");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.com.br");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec\u002Dinternational.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.com.ar");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.com.ar");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.com.au");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.com.au");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.at");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.at");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("br.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.be");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.be");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.ca");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.ca");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.cz");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.com.cz");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.cz");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.dk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.dk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.fi");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.fi");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.fr");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.fr");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("fr.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("fr.biogen.ca");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.de");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.de");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.ie");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.ie");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.it");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenitalia.it");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("it.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.co.jp");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.co.jp");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("jp.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.jp");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.nl");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.nl");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.no");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.no");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.pl");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.pl");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("pl.biogenidec.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.pt");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.pt");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.sk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.sk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.si");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.si");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("si.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.es");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.es");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.com.es");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("es.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.se");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.se");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("se.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.ch");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("fr.biogen.ch");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.ch");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.co.uk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.uk.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("uk.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.org.uk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.co.uk");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogenidec.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.investorhq.businesswire.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("cdn.biogenidec.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("cdn.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.newshq.businesswire.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("ar.biogen.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen\u002Dfrance.fr");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen\u002Dpoland.pl");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen\u002Dpharma.si");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.hu");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("sjobs.brassring.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.avature.net");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.co.nz\/");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("biogen.gcs\u002Dweb.com\/");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("spinraza.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("www.togetherinSMA.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("www.msactivesource.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		
			whitelist.push("www.avonex.com");
//alert("whitelistsuper------------->"+whitelistsuper);
//Whitelist= var whitelistsuper- do not show modal if domain is in this list(open in same tab).
		</script>
	
    



<!--[if IE 9]><html class="no-js lt-ie10"><![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!-->  <!--<![endif]-->



    
<script src="/etc/designs/dxp/corp/modernizer.min.js"></script>




    
<script src="/etc/designs/dxp/clientlib/video.min.js"></script>




    
<script src="/etc/designs/dxp/corp/clientlib/jquery-ui.min.js"></script><style type="text/css">.tk-freight-sans-pro,.tk-freight-sans-pro-light{font-family:"freight-sans-pro",sans-serif;}</style><style type="text/css">@font-face{font-family:freight-sans-pro;src:url(https://use.typekit.net/af/442215/000000000000000000010b5a/27/l?subset_id=1&fvd=n4&v=3) format("woff2"),url(https://use.typekit.net/af/442215/000000000000000000010b5a/27/d?subset_id=1&fvd=n4&v=3) format("woff"),url(https://use.typekit.net/af/442215/000000000000000000010b5a/27/a?subset_id=1&fvd=n4&v=3) format("opentype");font-weight:400;font-style:normal;font-stretch:normal;font-display:auto;}@font-face{font-family:freight-sans-pro;src:url(https://use.typekit.net/af/3df5fe/000000000000000000010b5b/27/l?subset_id=1&fvd=i4&v=3) format("woff2"),url(https://use.typekit.net/af/3df5fe/000000000000000000010b5b/27/d?subset_id=1&fvd=i4&v=3) format("woff"),url(https://use.typekit.net/af/3df5fe/000000000000000000010b5b/27/a?subset_id=1&fvd=i4&v=3) format("opentype");font-weight:400;font-style:italic;font-stretch:normal;font-display:auto;}@font-face{font-family:freight-sans-pro;src:url(https://use.typekit.net/af/ba2099/000000000000000000010b58/27/l?subset_id=1&fvd=n3&v=3) format("woff2"),url(https://use.typekit.net/af/ba2099/000000000000000000010b58/27/d?subset_id=1&fvd=n3&v=3) format("woff"),url(https://use.typekit.net/af/ba2099/000000000000000000010b58/27/a?subset_id=1&fvd=n3&v=3) format("opentype");font-weight:300;font-style:normal;font-stretch:normal;font-display:auto;}@font-face{font-family:freight-sans-pro;src:url(https://use.typekit.net/af/1ece10/000000000000000000010b59/27/l?subset_id=1&fvd=i3&v=3) format("woff2"),url(https://use.typekit.net/af/1ece10/000000000000000000010b59/27/d?subset_id=1&fvd=i3&v=3) format("woff"),url(https://use.typekit.net/af/1ece10/000000000000000000010b59/27/a?subset_id=1&fvd=i3&v=3) format("opentype");font-weight:300;font-style:italic;font-stretch:normal;font-display:auto;}@font-face{font-family:freight-sans-pro;src:url(https://use.typekit.net/af/8dd886/000000000000000000010b5c/27/l?subset_id=1&fvd=n5&v=3) format("woff2"),url(https://use.typekit.net/af/8dd886/000000000000000000010b5c/27/d?subset_id=1&fvd=n5&v=3) format("woff"),url(https://use.typekit.net/af/8dd886/000000000000000000010b5c/27/a?subset_id=1&fvd=n5&v=3) format("opentype");font-weight:500;font-style:normal;font-stretch:normal;font-display:auto;}@font-face{font-family:freight-sans-pro;src:url(https://use.typekit.net/af/441f33/000000000000000000010b5d/27/l?subset_id=1&fvd=i5&v=3) format("woff2"),url(https://use.typekit.net/af/441f33/000000000000000000010b5d/27/d?subset_id=1&fvd=i5&v=3) format("woff"),url(https://use.typekit.net/af/441f33/000000000000000000010b5d/27/a?subset_id=1&fvd=i5&v=3) format("opentype");font-weight:500;font-style:italic;font-stretch:normal;font-display:auto;}</style>





<script src="https://ssl.google-analytics.com/analytics.js"></script><script src="https://assets.adobedtm.com/3a6c1f61c9a73daa8c191c83bc1fe1137a5e6aa3/s-code-contents-2598f7d8abec5cd07fa6f7319625738de424f098.js"></script></head><body class="page_pipeline template_generic"><div>
<script src="//use.typekit.net/vot0txh.js"></script>
<script>try{Typekit.load();}catch(e){}</script>
</div>


    

    
    
<script src="/etc.clientlibs/cq/personalization/clientlib/underscore.min.js"></script>
<script src="/etc.clientlibs/cq/personalization/clientlib/personalization/kernel.min.js"></script>
<script type="text/javascript">
    $CQ(function() {
        CQ_Analytics.SegmentMgr.loadSegments("\/etc\/segmentation");
        CQ_Analytics.ClientContextUtils.init("\/etc\/clientcontext\/default", "\/content\/corporate\/en_us\/pipeline");

        
    });
</script>



    <script>
       var analytics_componentPath = '/apps/corp/components/page/generic';
        var analytics_pageName = 'corp:biogen:pipeline';
        var analytics_channel = 'corp:biogen:pipeline';
        var analytics_siteName = 'corp:biogen';
        var analytics_country = 'US';
        var analytics_language = 'en';
        var analytics_loginState = 'not logged\u002Din';
        var analytics_cmId = '';
    </script>



    
<script src="/etc/designs/dxp/clientlib/image.min.js"></script>
<script src="/etc/designs/dxp/clientlib/analytics.min.js"></script>










	
        
    
<script src="/etc/designs/dxp/clientlib/generic.min.js"></script>



		<input type="hidden" name="continuebtn" id="continuebtn">

        
		
		
		

     
    <div>
    
    
    
<link rel="stylesheet" href="/etc/designs/dxp/corp/corprefreshsearch.min.d9fdce6c72d80ab9d353cf95e4fa83db.css" type="text/css">
<link rel="stylesheet" href="/etc/designs/dxp/corp/corprefreshheaderfooter.min.d3f2ee2112be1d67d7251aaabb3c2b47.css" type="text/css">
<script src="/etc/designs/dxp/corp/corprefreshsearch.min.js"></script>
<script src="/etc/designs/dxp/corp/corprefreshheaderfooter.min.js"></script>



    <header class="header js-header fixed-top">
   <div class="inner">
      <div class="header-logo">
         <div>
            <a href="/en_us/home.html" class="logo">
               
                  <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg">
               
               
            </a>
         </div>
      </div>
      
      
      <div class="header-burger" role="megamenu">
         <button type="button" class="burger burger-open js-toggle-menu"></button>
         <button type="button" class="burger burger-close js-toggle-menu"></button>
      </div>
      <div class="menu js-menu">
         <div class="container-fluid container-fluid-lg">
            
               
               <!--Affiliation site Check Box -->
               
            
            <div>
               <div class="menu-in js-tabs">
                  <!-- BEGIN menu caption -->
                  <div class="menu1-item">
                     <div class="menu-item firstmenu1">
    
        <div>
            <a href="/en_us/home.html" class="logo d-block d-sm-block d-md-none">
                
                    <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                
                
            </a>
        </div>

        <ul class="menu-list js-tabs-caption">
            
                					
						<li class="menu-list-item" id="Who-We-Are">

							<a href="#" class="menu-list-link "> Who We Are</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Focus-on-Neuroscience">

							<a href="#" class="menu-list-link "> Focus on Neuroscience</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Biogen-Digital-Health">

							<a href="#" class="menu-list-link "> Biogen Digital Health</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Corporate-Responsibility">

							<a href="#" class="menu-list-link "> Corporate Responsibility</a>
						</li>					
                    
                        <li class="menu-search">
                            
 
 
<form id="searchSubmit" class="searchSubmit" method="post">
<div class="search js-search block block-green-light block-arr block-arr-light">
    <div class="search-input row">
          <div class="input col-md-12">
          
			<label class="hide-element" for="search">Search</label>
          	
            
				<input type="text" id="search_value" placeholder="How can we help you?">
            
            <div class="hidden show-search-error"></div>
			  <label class="hide-element" for="search">Submit</label>
              <button type="submit" id="search_submit" class="input-button">
              <i class="fa fa-search"></i>
              </button>
          
          </div>
     </div>
        <div class="search-footer block-footer">
            <div class="row search-footer-item">
    	        
            </div>
        </div>
 </div></form>

<input type="hidden" id="resultPage" name="resultPage" value="/content/corporate/en_us/search-results">
<input type="hidden" id="resultinsamepage" value="true">
<input type="hidden" id="queryParamSearchKey">
<input type="hidden" id="resultperpage" value="10">
<input type="hidden" id="searchfieldRequired">
<input type="hidden" id="searchresultsresppath">

 <div id="pod_search_result" class="search-results__content">
 
 <script type="text/javascript">

                </script>
                </div>


 <script>
 $('.js-tabs-caption').on('click', '.menu-list-item:not(.is-active)', function() {
  let index = $(this).index();

  $(this)
    .addClass('is-active').siblings().removeClass('is-active')
    .closest('.js-tabs').find('.js-tabs-content').removeClass('is-active').eq(index).addClass('is-active');
  return false;
});


$('.js-menu-back').on('click', function() {
  $(this).parent().removeClass('is-active');
  $(this).closest('.js-tabs').find('.menu-list-item').removeClass('is-active');
});

$('.js-search').on('keyup',function(){
	if($(this).find('input#search_value').val().length < 2){
        $('.show-search-error').text('Please enter at least 2 characters').removeClass('hidden');
    }
    else{
		$('.show-search-error').text('').addClass('hidden');
    }
});

 </script>				
 
                        </li>
                    
                
                
            
                					
						<li class="menu-list-item" id="Receive-Our-Updates">

							<a href="/en_us/newsletter-signup.html" class="menu-list-link "> Receive Our Updates</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Our-Stories">

							<a href="#" class="menu-list-link "> Our Stories</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="News-Releases">

							<a href="#" class="menu-list-link "> News Releases</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Investors">

							<a href="#" class="menu-list-link "> Investors</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Careers">

							<a href="#" class="menu-list-link "> Careers</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Medical-Professionals">

							<a href="#" class="menu-list-link "> Medical Professionals</a>
						</li>					
                    
                
                
            
                					
						<li class="menu-list-item" id="Global-Websites">

							<a href="#" class="menu-list-link "> Global Websites</a>
						</li>					
                    
                
                
            
        </ul>

        <!-- SOCIAL ICONS -->
        <div class="soc menu-soc">
            <div class="soc-text">Follow us:</div>
            <ul class="soc-list">
                <li class="soc-list-item">
                    <a href="http://www.twitter.com/biogen" target="_blank" class="soc-list-link bio-icon-twitter">
                        
                        
                    </a>

                </li>
            
                <li class="soc-list-item">
                    <a href="http://www.linkedin.com/company/biogen-/" target="_blank" class="soc-list-link bio-icon-linkedin">
                        
                        
                    </a>

                </li>
            
                <li class="soc-list-item">
                    <a href="http://www.youtube.com/biogen" target="_blank" class="soc-list-link bio-icon-youtube">
                        
                        
                    </a>

                </li>
            
                <li class="soc-list-item">
                    <a href="http://www.facebook.com/biogen" target="_blank" class="soc-list-link icons-facebook-light-blue">
                        
                        
                    </a>

                </li>
            </ul>
        </div>
    
</div>
                     <div class="menu-item secondmenu2">
                        <div class="wrap-description ">
                           



  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Who-We-Are">Who We Are</div>
    
    <div class="description-text">At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.</div>
	
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">ABOUT BIOGEN</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/about-us.html" class="catalog-link "> Company Overview</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/history-overview.html" class="catalog-link "> History</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/culture-elements.html" class="catalog-link "> Elements of Our Culture</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/diversity-inclusion.html" class="catalog-link "> Diversity &amp; Inclusion</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/contact.html" class="catalog-link "> Contact Us</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">LEADERSHIP</li>
        
        
            <li class="catalog-item">
                <a href="http://investors.biogen.com/governance/governance-documents" class="catalog-link externalicon" target="_blank"> Corporate Governance</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/board-of-directors.html" class="catalog-link "> Board of Directors</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/leadership.html" class="catalog-link "> Leadership Team</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">PHARMACEUTICAL OPERATIONS &amp; TECHNOLOGY</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/manufacturing.html" class="catalog-link "> Pharmaceutical Operations &amp; Technology</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/working-with-us.html" class="catalog-link "> Working with Us</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">GUIDING PRINCIPLES</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/transparency-reporting.html" class="catalog-link "> Transparency Reporting</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/code-of-business-conduct.html" class="catalog-link "> Code of Business Conduct</a>
            </li>
		
            <li class="catalog-item">
                <a href="/content/dam/corporate/en_us/pdfs/all-PDFs/Biogen-Anti-Slavery-and-Human-Trafficking-Statement.pdf" class="catalog-link "> Biogen Anti-Slavery and Human Trafficking Statement</a>
            </li>
		
            <li class="catalog-item">
                <a href="/content/dam/corporate/en_us/pdfs/BIOGEN_PricingPrinciplesInfographic_4-26-19.pdf" class="catalog-link "> Pricing Principles</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/global-tax-policy.html" class="catalog-link "> Global Tax Policy</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Focus-on-Neuroscience">Focus on Neuroscience</div>
    
    <div class="description-text">We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.</div>
	
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">DISEASE AREAS</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/multiple-sclerosis.html" class="catalog-link "> Multiple Sclerosis</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/spinal-muscular-atrophy.html" class="catalog-link "> Spinal Muscular Atrophy</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/alzheimers-disease.html" class="catalog-link "> Alzheimer's Disease</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">Biosimilars</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/biosimilars.html" class="catalog-link "> Biosimilars</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">PRODUCTS</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/product-portfolio.html" class="catalog-link "> Product Portfolio</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">SCIENCE FOR THE FUTURE</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/scientific-expertise.html" class="catalog-link "> Scientific Expertise</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/pipeline.html" class="catalog-link "> Pipeline</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">PATIENT RESOURCES</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/clinical-trials.html" class="catalog-link "> Clinical Trials</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/access-programs.html" class="catalog-link "> Early Access</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/financial-assistance.html" class="catalog-link "> Financial Assistance</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/patient-safety.html" class="catalog-link "> Patient Safety</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Biogen-Digital-Health">Biogen Digital Health</div>
    
    <div class="description-text">We aspire to transform patients’ lives and Biogen by making personalized &amp; digital medicine in neuroscience a reality. Powered by data science and digital technologies, we drive solutions to advance research, clinical care, and patient empowerment. We believe that now, more than ever, biology and technology should go hand-in-hand to better meet patient needs, while enabling a shift towards more prevention-focused, affordable, and equitable care. </div>
	
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">DISCOVER</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/biogen-digital-health.html" class="catalog-link "> Biogen Digital Health</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/biogen-digital-health-about.html" class="catalog-link "> About Us</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/biogen-digital-health-solutions.html" class="catalog-link "> Our Solutions</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/digital-health-stories.html" class="catalog-link "> Our Stories</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/biogen-digital-health-innovation.html" class="catalog-link "> External Innovation and Alliances</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Corporate-Responsibility">Corporate Responsibility</div>
    
    <div class="description-text">Biogen contributes to the communities where we live. We are committed to our employees, diversity, equity and inclusion, and environmental sustainability.</div>
	
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">CORPORATE RESPONSIBILITY</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/corporate-responsibility-overview.html" class="catalog-link "> Overview</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/healthy-climate-healthy-lives.html" class="catalog-link "> Healthy Climate, Healthy Lives™</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/yearinreview.html" class="catalog-link "> 2021 Year in Review</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/climate-strategy.html" class="catalog-link "> Environment</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/diversity-inclusion.html" class="catalog-link "> Diversity, Equity &amp; Inclusion</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/grants-giving.html" class="catalog-link "> Corporate Giving</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">COMMUNITY AND FOUNDATION</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/biogen-foundation.html" class="catalog-link "> Overview</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/star-initiative.html" class="catalog-link "> STAR Initiative</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/virtual-community-lab.html" class="catalog-link "> Community Lab</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Our-Stories">Our Stories</div>
    
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">OUR STORIES</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/stories.html" class="catalog-link "> Our Stories</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://investors.biogen.com/news" class="catalog-link externalicon" target="_blank"> News Releases</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="News-Releases">Latest News</div>
    
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">NEWS</li>
        
        
            <li class="catalog-item">
                <a href="http://investors.biogen.com/news" class="catalog-link externalicon" target="_blank"> News Releases</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Investors">Investors</div>
    
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">INVESTORS</li>
        
        
            <li class="catalog-item">
                <a href="http://investors.biogen.com/" class="catalog-link externalicon" target="_blank"> Investors Overview</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://investors.biogen.com/news" class="catalog-link externalicon" target="_blank"> News Releases</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://investors.biogen.com/events-and-presentations/upcoming-events" class="catalog-link externalicon" target="_blank"> Events</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://investors.biogen.com/events-and-presentations/presentations" class="catalog-link externalicon" target="_blank"> Presentations</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://investors.biogen.com/stock-information/stock-chart" class="catalog-link externalicon" target="_blank"> Stock Information</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://investors.biogen.com/stock-information/investor-faqs" class="catalog-link externalicon" target="_blank"> FAQs</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">RESOURCES</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/leadership.html" class="catalog-link "> Executive Leadership</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/board-of-directors.html" class="catalog-link "> Board of Directors</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/pipeline.html" class="catalog-link "> Pipeline</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Careers">Together, we pioneer. Together, we thrive. </div>
    
    <div class="description-text">We came to Biogen to solve the unsolvable. We stay to create new possibilities and grow together. We work fearlessly and go beyond because we care deeply about making a difference and changing lives. All legitimate correspondence from a Biogen employee will come from “@biogen.com” or “@smartrecruiters.com” email accounts.</div>
	
    <div class="description-catalog">
    	

		 
<div>
    <!-- SDI include (path: /en_us/megamenu/_jcr_content/par/l2navigation_1807334567/l3par/l3navigation_81913552/careersearch.nocache.html, resourceType: corp/components/layout/careersmasthead) -->
 <!-- Material Design icon font -->
   
    
    
<link rel="stylesheet" href="/etc/designs/dxp/corp/materialIcons.min.99ff926acb0f0673cd5a55ef401c7d13.css" type="text/css">



	
    
<link rel="stylesheet" href="/etc/designs/dxp/corp/careersmasthead.min.38d053c5076efb21b15e8c28028e675a.css" type="text/css">
<script src="/etc/designs/dxp/corp/careersmasthead.min.js"></script>



<section class="masthead mastheadalt masthead-investors" data-action-name="masthead" data-card-name="masthead" data-card-pos="pos-0">
    <div class="masthead__wrapper">
        <div class="masthead__image">

            <span class="masthead__background" data-picture="">

                <span data-src="/etc/designs/default/0.gif" data-media="(max-width: 767px)"></span>
            <span data-src="/content/corporate/en_us/megamenu/_jcr_content/par/l2navigation_1807334567/l3par/l3navigation_81913552/careersearch/image/desktop.img.full.high.jpg/1525114975915.jpg" data-media="(min-width: 768px) and (max-width: 1260px)"></span>
            <span data-src="/etc/designs/default/0.gif" data-media="(min-width: 1261px)"><img alt="" title="" class="" src="/etc/designs/default/0.gif"></span>

            <noscript>
                <img src="/content/corporate/en_us/megamenu/_jcr_content/par/l2navigation_1807334567/l3par/l3navigation_81913552/careersearch/image/desktop.img.full.high.jpg/1525114975915.jpg"/>
            </noscript>
            </span>
			
				<div class="masthead__columns mastheadalt desktoplight tabletlight mobilelight">
					<div class="masthead__text-content">
						
						<div class="masthead__heading"></div>
						
						<div class="masthead__text"></div>
						<div class="masthead__actions">
							<div class="cta-mastheadalt-wrapper" style="color:#5792c5;font-weight:700;">
								EXPLORE OPPORTUNITIES
							</div>
							<div class="input-group add-on search" style="width:100%">
								<label class="hide-element" for="search">Search</label>
								<input class="form-control" autocomplete="off" placeholder="Search Careers" name="srch-term" id="srch-term" type="text">
								<div class="input-group-btn">
									<label class="hide-element" for="search">Submit</label>
									<button class="btn btn-default serach" type="submit" style="background-color:#A8D05B;height: 34px;margin-bottom: 5px;"><i class="glyphicon glyphicon-search"></i></button>
									<input type="hidden" id="resultsPath" name="resultsPath" value="/content/corporate/en_us/careers-search">
								</div>
							</div>
							<div class="focus-check" style="outline:1px solid transparent;" tabindex="-1">
							<div class="category dropdown1-wrapper" name="category" list="category" autocomplete="off" style="display:none;width:49%;margin:0;padding:0;background-color: white;">
							<div class="aem-dropdown dropdown">
	                           <div class="aem-select" style="height:30px;">
	                           	<div class="aem-select-content" data-text="Category" style="width: 100%;height: 29px;overflow: auto;padding:2px;"></div>
		                           <i class="material-icons down-icon"></i>
	                             </div>
							   <ul class="dropdown1-menu ae-hide" style="width:100%;overflow-y:scroll;height:200px;position:absolute;" id="category">
								<li value="">All</li>
								
									<li value="Administrative">Administrative</li>
									
									<li value="Business Development">Business Development</li>
									
									<li value="Commercial">Commercial</li>
									
									<li value="Corporate Affairs">Corporate Affairs</li>
									
									<li value="Engineering">Engineering</li>
									
									<li value="Facilities &amp; Infrastructure">Facilities &amp; Infrastructure</li>
									
									<li value="Finance &amp; Accounting">Finance &amp; Accounting</li>
									
									<li value="Human Resources">Human Resources</li>
									
									<li value="Information Technology">Information Technology</li>
									
									<li value="Legal &amp; Compliance">Legal &amp; Compliance</li>
									
									<li value="Manufacturing">Manufacturing</li>
									
									<li value="Market Access">Market Access</li>
									
									<li value="Medical Affairs">Medical Affairs</li>
									
									<li value="Patient Services">Patient Services</li>
									
									<li value="Procurement">Procurement</li>
									
									<li value="Quality">Quality</li>
									
									<li value="Regulatory">Regulatory</li>
									
									<li value="Research &amp; Development">Research &amp; Development</li>
									
									<li value="Sales &amp; Marketing">Sales &amp; Marketing</li>
									
									<li value="Supply Chain Operations">Supply Chain Operations</li>
									
						    	</ul>
							</div>
							</div>
							
							<div class="location dropdown11-wrapper" name="location" list="location" autocomplete="off" style="display:none;width:49%;margin:0;padding:0;float:right;background-color: white;">
							<div class="aem-dropdown1 dropdown">
	                           <div class="aem-select1" style="height:30px;">
	                           	<div class="aem-select-content1" data-text="Location" style="width: 100%;height: 29px;overflow: auto;padding:2px;"></div>
		                           <i class="material-icons down-icon"></i>
	                             </div>
							
							<ul class="dropdown11-menu ae-hide" style="width:100%;overflow-y:scroll;height:200px;position:absolute;" id="location">
								<li value="">All</li>
								
								<li value="Australia-Sydney">Australia-Sydney</li>
								
								<li value="Brazil-Sao Paulo">Brazil-Sao Paulo</li>
								
								<li value="China-Beijing">China-Beijing</li>
								
								<li value="China-Shanghai">China-Shanghai</li>
								
								<li value="Colombia-Bogota">Colombia-Bogota</li>
								
								<li value="Czech Republic-Praha">Czech Republic-Praha</li>
								
								<li value="Denmark-Copenhagen">Denmark-Copenhagen</li>
								
								<li value="Field Locations">Field Locations</li>
								
								<li value="France-Paris">France-Paris</li>
								
								<li value="Germany-Munich">Germany-Munich</li>
								
								<li value="Hungary-Budapest">Hungary-Budapest</li>
								
								<li value="Italy-Milano">Italy-Milano</li>
								
								<li value="Japan-Tokyo">Japan-Tokyo</li>
								
								<li value="Korea-Seoul">Korea-Seoul</li>
								
								<li value="Mexico-Mexico City">Mexico-Mexico City</li>
								
								<li value="Netherlands-Badhoevedorp">Netherlands-Badhoevedorp</li>
								
								<li value="Poland-Warsaw">Poland-Warsaw</li>
								
								<li value="Slovak Republik-Bratislava">Slovak Republik-Bratislava</li>
								
								<li value="Spain-Madrid">Spain-Madrid</li>
								
								<li value="Switzerland -Baar Affiliate">Switzerland -Baar Affiliate</li>
								
								<li value="Switzerland-Baar Headquarters">Switzerland-Baar Headquarters</li>
								
								<li value="UK-Maidenhead">UK-Maidenhead</li>
								
								<li value="US-DC-Washington DC">US-DC-Washington DC</li>
								
								<li value="US-MA-Cambridge">US-MA-Cambridge</li>
								
								<li value="US-MA-Weston">US-MA-Weston</li>
								
								<li value="US-NC-Durham">US-NC-Durham</li>
								
								<li value="US-NC-Research Triangle Park-5000 Davis Drive">US-NC-Research Triangle Park-5000 Davis Drive</li>
								
								<li value="US-NC-Research Triangle Park-900 Davis Drive">US-NC-Research Triangle Park-900 Davis Drive</li>
								
								<li value="US-Remote USA">US-Remote USA</li>
								
							</ul>
							</div>
							</div>
							
							</div>
						</div>
						<div class="resume__text" style="padding:2%"></div>
					</div>
				</div>
			</div>
        </div>
</section>


   <ul class="catalog">
        <li class="catalog-title title"></li>
        
     	 </ul>


</div>





       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">CAREERS</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/careers.html" class="catalog-link "> Careers Overview</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/careers-faqs.html" class="catalog-link "> FAQs</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/job-categories.html" class="catalog-link "> Job Categories</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://smrtr.io/3ThFX" class="catalog-link externalicon"> Talent Community</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/building-your-career.html" class="catalog-link "> Building Your Career</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/careers-how-we-hire.html" class="catalog-link "> How We Hire</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/diversity-inclusion.html" class="catalog-link "> Diversity, Equity and Inclusion</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/culture-elements.html" class="catalog-link "> Elements of Our Culture</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/careers-benefits.html" class="catalog-link "> Benefits</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/fraudulent-job-postings.html" class="catalog-link "> Authorized Recruitment Activities</a>
            </li>
		
     	 </ul>

</div>



       

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">Student &amp; post-graduate opportunities</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/students-graduates.html" class="catalog-link "> Students and Graduates</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/pharmd-fellowships.html" class="catalog-link "> PharmD Fellowships</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/phd-fellowship.html" class="catalog-link "> PhD Fellowship</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/postdoctoral-program" class="catalog-link "> Postdoc Program</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Medical-Professionals">Medical Professionals</div>
    
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        <li class="catalog-title title">Resources</li>
        
        
            <li class="catalog-item">
                <a href="/en_us/medical-professionals.html" class="catalog-link "> For Medical Professionals</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/transparency-reporting.html" class="catalog-link "> Transparency Reporting</a>
            </li>
		
            <li class="catalog-item">
                <a href="http://medinfo.biogen.com/" class="catalog-link externalicon" target="_blank"> Medical Information</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.com/en_us/grants-giving.html" class="catalog-link externalicon"> Corporate Giving</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


  <div class="description js-tabs-content">
  <div>
	<div class="d-block d-sm-block d-md-none">
                  <a href="/en_us/home.html" class="logo">
                    
                        <img src="/content/dam/corporate/en_us/images/svg/biogen-logo-refresh-new.svg" title="" alt="">
                    
					
                  </a>
                </div>
				</div>
    <button type="button" class="title description-back js-menu-back"> <i class="fa fa-angle-left"></i><span>Menu</span></button>

    <div class="description-title" id="Global-Websites">Global Websites</div>
    
    <div class="description-catalog">
    	

		 


<div>

    	<ul class="catalog">
    	
        
            <li class="catalog-item">
                <a href="https://www.biogen.com" class="catalog-link externalicon"> Global site</a>
            </li>
		
            <li class="catalog-item">
                <a href="/en_us/biogen-international.html" class="catalog-link "> International HQ</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://ar.biogen.com/" class="catalog-link externalicon" target="_blank"> Argentina</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.com.au/" class="catalog-link externalicon"> Australia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.at/" class="catalog-link externalicon" target="_blank"> Austria</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.be/" class="catalog-link externalicon" target="_blank"> Belgium</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://br.biogen.com/" class="catalog-link externalicon" target="_blank"> Brazil</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.ca/" class="catalog-link externalicon" target="_blank"> Canada</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.cn/" class="catalog-link externalicon"> China</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biibcolombia.co" class="catalog-link externalicon"> Colombia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.hr" class="catalog-link externalicon"> Croatia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.com.cz/" class="catalog-link externalicon"> Czech Republic</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.dk/" class="catalog-link externalicon" target="_blank"> Denmark</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.ee" class="catalog-link externalicon"> Estonia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.fi/" class="catalog-link externalicon" target="_blank"> Finland</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen-france.fr/" class="catalog-link externalicon" target="_blank"> France</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.de/" class="catalog-link externalicon" target="_blank"> Germany</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.hu/" class="catalog-link externalicon" target="_blank"> Hungary</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.ie/" class="catalog-link externalicon" target="_blank"> Ireland</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogenitalia.it/" class="catalog-link externalicon" target="_blank"> Italy</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.co.jp/" class="catalog-link externalicon" target="_blank"> Japan</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://kr.biogen.com" class="catalog-link externalicon" target="_blank"> Korea</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.lv" class="catalog-link externalicon"> Latvia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.lt" class="catalog-link externalicon"> Lithuania</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.com.mx" class="catalog-link externalicon"> Mexico</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.nl/" class="catalog-link externalicon" target="_blank"> The Netherlands</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.co.nz/" class="catalog-link externalicon" target="_blank"> New Zealand</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.no/" class="catalog-link externalicon" target="_blank"> Norway</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen-poland.pl/" class="catalog-link externalicon" target="_blank"> Poland</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.pt/" class="catalog-link externalicon" target="_blank"> Portugal</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen-gulf.com/" class="catalog-link externalicon"> Saudi Arabia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.sk/" class="catalog-link externalicon" target="_blank"> Slovak Republic</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen-pharma.si/" class="catalog-link externalicon" target="_blank"> Slovenia</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.com.es/" class="catalog-link externalicon"> Spain</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.se/" class="catalog-link externalicon" target="_blank"> Sweden</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.ch/" class="catalog-link externalicon" target="_blank"> Switzerland</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.tw/" class="catalog-link externalicon"> Taiwan</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen-gulf.com/" class="catalog-link externalicon"> UAE</a>
            </li>
		
            <li class="catalog-item">
                <a href="https://www.biogen.uk.com/" class="catalog-link externalicon" target="_blank"> United Kingdom</a>
            </li>
		
     	 </ul>

</div>



       
    </div>

</div>


                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
      </div>
   </div>
</header>
    </div><iframe sandbox="allow-scripts allow-same-origin" title="Adobe ID Syncing iFrame" id="destination_publishing_iframe_biogen_0" name="destination_publishing_iframe_biogen_0_name" src="https://biogen.demdex.net/dest5.html?d_nsid=0#https%3A%2F%2Fwww.biogen.com" style="display: none; width: 0px; height: 0px;" class="aamIframeLoaded"></iframe>

    

		
		
		
<div class="main-content-wrapper" role="main">
		


<div>
<div class="js-page-controller-action"><section class="masthead masthead-investors" data-action-name="masthead" data-card-name="Pipeline" data-card-pos="pos-footer">
    <div class="masthead__wrapper"> 
        <div class="masthead__image">

            <span class="masthead__background" data-picture="">

                <span data-src="/content/corporate/en_us/pipeline/_jcr_content/hero/image/mobile.img.full.high.jpg/1525688502084.jpg" data-media="(max-width: 767px)"></span>
                <span data-src="/content/corporate/en_us/pipeline/_jcr_content/hero/image/desktop.img.full.high.jpg/1525688441823.jpg" data-media="(min-width: 768px) and (max-width: 1260px)"></span>
                <span data-src="/content/corporate/en_us/pipeline/_jcr_content/hero/image/xl.img.full.high.jpg/1525688432821.jpg" data-media="(min-width: 1261px)"><img alt="" title="" class="" src="/content/corporate/en_us/pipeline/_jcr_content/hero/image/xl.img.full.high.jpg/1525688432821.jpg"></span>

                <noscript>
                    <img src="/content/corporate/en_us/pipeline/_jcr_content/hero/image/desktop.img.full.high.jpg/1525688441823.jpg"/>
                </noscript>
            </span>
            
            <div class="masthead__columns">
                <div class="masthead__text-content"> 
                    
                    <h1 class="masthead__heading">Pipeline</h1>
                    
                    <div class="masthead__text"></div>
                    
                </div>
            </div>
        </div>
    </div>  
</section></div>
</div>

		


<div class="pipelinecomponent hr base parbase section">



    

    <div class="product-pipeline">
      
            <div class="product-pipeline__filters">
            <div class="product-pipeline__filterby--text">Filter by:</div>
			
	            <div class="product-pipeline__filter product-pipeline__therapeutic-areas">
	                <div class="product-pipeline__filter-trigger">
	                    <span class="text">All disease areas</span>
	                    <span class="bio-icon-arrow-thin-down"></span>
	                </div>
	
	                
	                <ul>
	                    <li class="selected" data-category="allAreas">All disease areas</li>
	                    
	                        <li data-category="therapy-area:alzheimers-disease">Alzheimer's Disease</li>
	                    
	                        <li data-category="therapy-area:amyotrophic-lateral-sclerosis">Amyotrophic Lateral Sclerosis (ALS)</li>
	                    
	                        <li data-category="therapy-area:angelman-syndrome">Angelman Syndrome</li>
	                    
	                        <li data-category="therapy-area:brain-contusion">Brain Contusion</li>
	                    
	                        <li data-category="therapy-area:essential-tremor">Essential Tremor</li>
	                    
	                        <li data-category="therapy-area:lupus">Lupus</li>
	                    
	                        <li data-category="therapy-area:multiple-sclerosis">Multiple Sclerosis (MS)</li>
	                    
	                        <li data-category="therapy-area:multiple-system-atrophy">Multiple System Atrophy (MSA)</li>
	                    
	                        <li data-category="therapy-area:Neuropsychiatry">Neuropsychiatry</li>
	                    
	                        <li data-category="therapy-area:ophthalmology">Ophthalmology</li>
	                    
	                        <li data-category="therapy-area:pain">Pain</li>
	                    
	                        <li data-category="therapy-area:parkinsons-disease">Parkinson's Disease</li>
	                    
	                        <li data-category="therapy-area:spinal-muscular-atrophy">Spinal Muscular Atrophy (SMA)</li>
	                    
	                        <li data-category="therapy-area:Spinocerebellar-ataxia-type-3">Spinocerebellar ataxia type 3</li>
	                    
	                        <li data-category="therapy-area:stroke">Stroke</li>
	                    
	                        <li data-category="therapy-area:immunologic-conditions">Various immunologic conditions</li>
	                    
	                </ul>
	
	            </div>
            
            
            <div class="product-pipeline__filter product-pipeline__phases">
                <div class="product-pipeline__filter-trigger">
                    <span class="text">All phases</span>
                    <span class="bio-icon-arrow-thin-down"></span>
                </div>

                
                <ul>
                    <li class="selected" data-category="allPhases">All phases</li>
                    <li data-category="phaseA">Filed</li>
                    <li data-category="phase3">Phase 3</li> 
                    <li data-category="phase2">Phase 2</li>
                    <li data-category="phase1">Phase 1</li>
                </ul>
            </div>
            
          </div>
		

        <div class="product-pipeline__products">
            <div class="product-pipeline__products-headings">

                <div class="phaseIndicator"><span class="mobile">Phase</span></div>
                <div class="phasesHeadings">
                    <ul>
                        <li><span class="mobile">1</span><span class="desktop">Phase 1</span></li>
                        <li><span class="mobile">2</span> <span class="desktop">Phase 2</span></li>
                        <li><span class="mobile">3</span><span class="desktop">Phase 3</span></li>
                        <li>Filed</li>                
                    </ul>
                </div>
            </div>
            <div class="product-pipeline__scrollbarcontainer">
                <div class="scrollbar product-pipeline__scrollbar">
                    <div class="track">
                        <div class="thumb">
                            <div class="end"></div>
                        </div>
                    </div>
                </div>  
            </div>

            <div class="product-pipeline__viewport viewport">
                <div class="product-pipeline__overview overview">
                    <ul class="product-pipeline__products-wrapper">
                        <div class="product-pipeline__products--separator"></div>

                        
                            <li id="Aducanumab" class="product-pipeline__products--product phaseA therapy-area:alzheimers-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>Aducanumab (Aβ mAb)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Alzheimer’s disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Developed in collaboration with Eisai Co., Ltd.</p>
<p>Licensed from Neurimmune.</p>
<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide<sup>1</sup>.</p>
<p>Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. Aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of the disease.</p>
<p>Learn more about <a></a><a href="https://clinicaltrials.gov/ct2/show/NCT02484547?term=aducanumab&amp;draw=2&amp;rank=5" target="_blank">EMERGE</a>&nbsp;and <a></a><a href="https://clinicaltrials.gov/ct2/show/NCT02477800?term=aducanumab&amp;draw=2&amp;rank=6" target="_blank">ENGAGE</a>, clinical trials for Alzheimer’s disease.</p>
<p>&nbsp;</p>
<p><sup>1</sup> World Health Organization Dementia a Public Health Priority. <a href="http://www.who.int/mental_health/publications/dementia_report_2012/en/">http://www.who.int/mental_health/publications/dementia_report_2012/en/</a>. Accessed 23 May 2016.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB067" class="product-pipeline__products--product phase3 therapy-area:amyotrophic-lateral-sclerosis">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>Tofersen (SOD1 ASO)</b></p>
 </div>
                                        <div class="product__info-disease"><p>SOD-1-Amyotrophic lateral sclerosis (ALS)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Licensed from Ionis Pharmaceuticals, Inc.</p>
<p>ALS is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.</p>
<p><b>How this investigational therapy could help:&nbsp;</b></p>
<p>In a rare form of ALS, a mutated protein called superoxide dismutase (SOD1) has been associated with the degeneration of motor neurons. SOD1-ALS is the second most common form of inherited or familial ALS, accounting for up to 20 percent of familial ALS and 2 percent of all ALS cases.&nbsp;</p>
<p>BIIB067 (tofersen) is thought to reduce the production of SOD1 protein and is being evaluated to see if it can potentially slow the fatal progression of SOD1-ALS.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB093-glibenclamide" class="product-pipeline__products--product phase3 therapy-area:stroke">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB093 (IV glibenclamide)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Large hemispheric infarction</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke. The target indication for BIIB093 (IV glibenclamide) is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.</p>
<p>&nbsp;</p>
<p><b>How this investigational therapy could help:</b></p>
<p>In pre-clinical studies, BIIB093 (IV glibenclamide) has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of&nbsp;BIIB093 to reduce brain swelling, disability and the risk of death in patients with LHI.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="Lecanemab" class="product-pipeline__products--product phase3 therapy-area:alzheimers-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>Lecanemab (Aβ mAb)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Alzheimer’s disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Eisai Co., Ltd.</p>
<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide<sup>1</sup>.</p>
<p>Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain.&nbsp;Lecanemab (Aβ mAb) is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.</p>
<p>&nbsp;</p>
<p><sup>1</sup> World Health Organization Dementia a Public Health Priority.<u> http://www.who.int/mental_health/publications/dementia_report_2012/en/</u>. Accessed 23 May 2016.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="SB15" class="product-pipeline__products--product phase3 therapy-area:ophthalmology">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>SB15 (biosimilar referencing EYLEA®)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Various ophthalmologic conditions</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>*Licensed from Samsung Bioepis</p>
<p>SB15 is a proposed biosimilar of the reference product aflibercept (EYLEA®).&nbsp; EYLEA is widely used to treat ophthalmologic conditions such as neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME and myopic choroidal neovascularization (CNV).</p>
<p>How this therapy could help:</p>
<p>Biosimilars play a key role in helping generate meaningful savings for payers and health systems globally, while enabling increased access for patients to biologic therapies.&nbsp; Biosimilars help create the budgetary headroom necessary to fund future innovations for society.&nbsp;</p>
<p><a href="https://www.clinicaltrials.gov/ct2/show/NCT04450329?term=sb15&amp;draw=2&amp;rank=1">Learn more about the SB15 clinical trial.</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="dapirolizumab-pegol" class="product-pipeline__products--product phase3 therapy-area:lupus">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>Dapirolizumab pegol (anti-CD40L)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Systemic lupus erythematosus</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with UCB</p>
<p>This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in lupus patients.</p>
<p>Learn more about the <a href="https://clinicaltrials.gov/ct2/show/NCT04294667">PHOENYCS GO</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT04976322">PHOENYCS GLIDE</a> clinical trials.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB059" class="product-pipeline__products--product phase3 therapy-area:lupus">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB059 (anti-BDCA2)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Systemic lupus erythematosus</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>BDCA2 is a protein present in specific cells within the immune system. An antibody against BDCA2 can potentially interrupt production of interferons, inflammatory molecules that are increased in patients with lupus and contribute to disease activity.&nbsp;</p>
<p>Learn more about <a href="https://clinicaltrials.gov/ct2/show/NCT04895241">TOPAZ-1</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT04961567">TOPAZ-2</a>, clinical trials for systemic lupus erythematosus.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB125" class="product-pipeline__products--product phase3 therapy-area:Neuropsychiatry">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB125 (zuranolone)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Major depressive disorder (MDD)<b></b></p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Sage Therapeutics, Inc.</p>
<p>Major depressive disorder (MDD) is a common but serious mood disorder in which people experience depressive symptoms that impair their social, occupational, educational or other important functioning, such as a depressed mood or loss of interest or pleasure in daily activities, consistently for at least a two-week period. It is estimated that approximately 17 million people in the U.S. and more than 250 million people worldwide suffer from MDD each year.</p>
<p><b>Why we believe this investigational drug has the potential to help:</b></p>
<p>Zuranolone is an investigational oral neuroactive steroid GABA-A receptor positive allosteric modulator. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes significantly to regulating brain function.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB125-1" class="product-pipeline__products--product phase3 therapy-area:Neuropsychiatry">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB125 (zuranolone)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Postpartum depression (PPD)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Sage Therapeutics, Inc.</p>
<p>Postpartum depression is a major depressive episode that can occur during pregnancy or postpartum and is one of the most common medical complications during and after pregnancy. In the U.S., an estimated 1 in 8 mothers experience symptoms of PPD, which equates to approximately 500,000 annual cases.</p>
<p><b>Why we believe this investigational drug has the potential to help:</b></p>
<p>Zuranolone is an investigational oral neuroactive steroid GABA-A receptor positive allosteric modulator. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system, and contributes significantly to regulating brain function.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB800" class="product-pipeline__products--product phase3 therapy-area:immunologic-conditions">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB800 (biosimilar referencing ACTEMRA®, BAT1806)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Various immunologic conditions</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Licensed from Bio-Thera Solutions, Ltd.</p>
<p>BIIB800 (BAT1806) is a proposed biosimilar of the reference product referencing ACTEMRA®/RoACTEMRA® (tocilizumab).&nbsp; ACTEMRA/RoACTEMRA’s primary indication is for moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and cytokine release syndrome.</p>
<p><b>Why we believe this investigational drug has the potential to help:</b></p>
<p>Biosimilars play a key role in helping to generate meaningful savings for payers and health systems globally, while enabling increased access for patients to biologic therapies.&nbsp; Biosimilars help drive healthcare sustainability, creating the budgetary headroom necessary to fund future innovations for society.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/study/NCT03830203">Learn more about BIIB800 clinical trial</a>.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB074" class="product-pipeline__products--product phase2 therapy-area:pain">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB074&nbsp;(vixotrigine)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Trigeminal neuralgia</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Trigeminal neuralgia is an extremely painful, rare condition usually involving one side of the face. Trigeminal neuralgia is characterized by sudden, brief, stabbing, recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing, talking or brushing teeth (trigger factors). The pain follows one or more branches of the trigeminal nerve, which provides nerve sensation from the mouth, face and the front of the scalp. The intensity, frequency and unpredictability of the pain results in profound effects on the quality of life of patients and their caregivers.</p>
<p>&nbsp;</p>
<p><b>How this investigational therapy could help:</b></p>
<p>Vixotrigine is a voltage- and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB074-vixotrigine" class="product-pipeline__products--product phase2 therapy-area:pain">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB074 (vixotrigine)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Small fiber neuropathy (SFN)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Small fiber neuropathy (SFN) is a condition characterized by severe pain attacks that typically begin in the feet or hands. Patients may experience spontaneous burning, itching or shooting pain which may be triggered by stimuli that are ordinarily not painful, such as hot or cold temperatures or light touch. SFN is a neuropathic pain condition which can have different causes, such as diabetes or vitamin B12 deficiency, or the cause may be unknown.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>Vixotrigine is a voltage- and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03339336">Learn more about the clinical trial for BIIB074 in SFN</a>. &nbsp;</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB093" class="product-pipeline__products--product phase2 therapy-area:brain-contusion">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB093 (IV glibenclamide)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Brain Contusion</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Brain contusions (bleeding and surrounding swelling within the brain) are a devastating complication associated with blunt head trauma. Within the first hours or days following a head injury, contusions may expand, via the growth of a hematoma (bleeding) and worsening edema (swelling) in the surrounding brain tissues. This can cause rapid neurologic deterioration, including compression of vital neurologic centers, and in some cases, brain death. Expansion of contusions, which may occur in up to 50 percent of cases, is associated with significant morbidity and mortality after brain injury.</p>
<p>&nbsp;</p>
<p><b>How this investigational therapy could help:</b><i></i></p>
<p>In pre-clinical studies, BIIB093 (IV glibenclamide) has been shown to block SUR1-TRPM4 channels that contribute to ongoing bleeding in the brain and worsening of edema following brain trauma. BIIB093 is being investigated to see if it may potentially reduce the number of patients who experience expansion of their contusions during their ICU stay.</p>
<p><a></a><a></a><a href="https://clinicaltrials.gov/ct2/show/NCT03954041?term=BIIB093&amp;rank=1" target="_blank">Learn more about the BIIB093 clinical trial.</a></p>
<p>&nbsp;</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB104" class="product-pipeline__products--product phase2 therapy-area:Neuropsychiatry">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB104 (AMPA)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Cognitive impairment associated with schizophrenia (CIAS)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Acquired from Pfizer Inc.&nbsp;</p>
<p>Worldwide there are greater than 20 million people living with schizophrenia and it is estimated that the majority of them live with some degree of cognitive impairment attributable to the disease. When cognition is impaired, processing information, planning, and remembering become difficult or impossible. Cognition can be impaired in multiple neurological diseases and neurocognitive disorders, including schizophrenia.&nbsp;</p>
<p>BIIB104 is a first-in-class, Phase 2b ready asset for CIAS</p>
<p><b>How this investigational therapy could help:</b></p>
<p>BIIB104 is an AMPA receptor potentiator designed to facilitate neurotransmission in the central nervous system, a process which can be disrupted in a number of neurological diseases and neurocognitive disorders, including schizophrenia.</p>
<p><a href="https://www.tallyschizophreniatrial.com/">Learn more about TALLY, a clinical trial for cognitive impairment associated with schizophrenia</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB124" class="product-pipeline__products--product phase2 therapy-area:essential-tremor">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB124 (SAGE-324)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Essential Tremor</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Sage Therapeutics, Inc.</p>
<p>Essential tremor is one of the most common movement disorders in the United States, affecting an estimated 6.4 million Americans. For essential tremor patients, uncontrollable shaking of the hands, head, voice or legs creates difficulty eating, dressing, writing and pursuing other day-to-day tasks.</p>
<p><b>Why we believe this investigational drug has the potential to help:</b></p>
<p>BIIB124 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). NAS GABAA receptor PAMs bind to both synaptic and extrasynaptic GABAA receptors, enhancing inhibitory activity of the GABAergic system, the major inhibitory neurotransmission system in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in maintaining balanced neuronal activity in the brain. GABA dysregulation has been implicated in the pathophysiology of ET.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="TMS007" class="product-pipeline__products--product phase2 therapy-area:stroke">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB131 (TMS-007)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Stroke</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke.</p>
<p style="text-align: justify;">How this investigational therapy could help:</p>
<p>BIIB131 (TMS-007) is a plasminogen activator with a novel mechanism of action associated with breaking down blood clots and is believed to inhibit local inflammation at the site of thrombosis. This unique combination could position BIIB131 (TMS-007) as a best in class thrombolytic for individuals with acute ischemic stroke (AIS) with potential for an extended treatment window as compared to current thrombolytic agents.</p>
<p>BIIB131 (TMS-007) is a small molecule which has previously demonstrated an acceptable safety profile in a Phase 1 study and has also reduced infarct volume (area of dead tissue resulting from failure of blood supply) in experimental, preclinical, embolic and thrombotic stroke models.</p>
<p>BIIB131 (TMS-007) was evaluated in a double-blind, placebo-controlled Phase 2a study conducted in Japan, which was designed to investigate the safety and efficacy of a single IV administration of TMS-007 in approximately 90 patients with AIS up to 12 hours after stroke onset. Results demonstrated BIIB131 was generally well tolerated up to 6 mg/kg across broad AIS population and improved functional outcome as measured by the modified Rankin scale, a registrational endpoint of functional independence, at day 90 vs placebo.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="Orelabrutinib" class="product-pipeline__products--product phase2 therapy-area:multiple-sclerosis">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>Orelabrutinib (BTK inhibitor)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Multiple Sclerosis</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with InnoCare Pharma.</p>
<p>MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.</p>
<p><b>Why we believe this investigational drug has the potential to help:</b></p>
<p>Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) that has the potential to inhibit B cell receptor signaling and effector functions, hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of myeloid cells of the immune system via another receptor of this cell (Fcγ receptor signaling (FcγRs)). This proposed dual mechanism of action is hypothesized to result in greater efficacy than inhibition of B cells alone. With its high kinase selectivity and high penetrance of the central nervous system, orelabrutinib has the potential to be a best-in-class BTK inhibitor for relapsing forms of MS and progressive forms of MS, as well as complementing our existing portfolio.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT04711148?term=orelabrutinib&amp;draw=2&amp;rank=4">Learn more about the orelabrutinib clinical trial</a>.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB113" class="product-pipeline__products--product phase1 therapy-area:alzheimers-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB113 (OGA inhibitor)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Alzheimer’s disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide<sup>1</sup>.</p>
<p>Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.</p>
<p>Tau pathology is a histopathological hallmark of AD and the progression of tau pathology closely correlates with clinical progression of the disease, indicating that the development of tau aggregates is an underlying pathogenic event and that targeting tau may provide therapeutic benefit.</p>
<p>Why we believe this investigational drug has the potential to help:</p>
<p>BIIB113 is a small molecule inhibitor of O-GlcNACase<i>,</i> or OGA, an enzyme believed to catalyze the removal of O-GlcNAc post-translation modification of tau protein. By inhibiting OGA, we aim to increase the O-GlcNAcylation of tau to potentially inhibit tau aggregation and thereby slow clinical decline.&nbsp;</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT05195008">Learn more about the BIIB113 clinical trial</a>.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB076" class="product-pipeline__products--product phase1 therapy-area:alzheimers-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB076 (anti-tau mAb)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Alzheimer's disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide<sup>1</sup>.</p>
<p>Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.<b></b></p>
<p>&nbsp;</p>
<p><b>How this investigational therapy could help:</b></p>
<p>The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in&nbsp;the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB076 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain.</p>
<p><sup>1</sup> World Health Organization Dementia a Public Health Priority.<u> http://www.who.int/mental_health/publications/dementia_report_2012/en/</u>. Accessed 23 May 2016.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB080" class="product-pipeline__products--product phase1 therapy-area:alzheimers-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB080 (tau ASO)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Alzheimer's disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Licensed from Ionis Pharmaceuticals, Inc.</p>
<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide<sup>1</sup>. Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques and tau tangles, abnormal protein deposits that build up in&nbsp;the brain and in the brain cells. BIIB080 (tau ASO)&nbsp;is an antisense oligonucleotide (ASO) that may reduce production of the tau protein and its accumulation in brain cells, potentially slowing the progress of the disease.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03186989?term=ionis&amp;draw=1&amp;rank=3" target="_blank">Learn more about the BIIB080 (tau ASO) clinical trial</a></p>
<p><sup>1</sup>World Health Organization Dementia a Public Health Priority.&nbsp;<a href="http://www.who.int/mental_health/publications/dementia_report_2012/en/" target="_blank">http://www.who.int/mental_health/publications/dementia_report_2012/en/</a>. Accessed 23 May 2016.&nbsp;</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB091" class="product-pipeline__products--product phase1 therapy-area:multiple-sclerosis">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB091 (BTK inhibitor)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Multiple sclerosis (MS)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.</p>
<p>How this investigational therapy could help:</p>
<p>BIIB091 selectively inhibits Burton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the Myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)).</p>
<p><a></a><a href="https://clinicaltrials.gov/ct2/show/NCT03943056?term=257HV101&amp;rank=1" target="_blank">Learn more about the BIIB091 clinical trial</a>.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB094" class="product-pipeline__products--product phase1 therapy-area:parkinsons-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB094 (LRRK2 ASO)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Parkinson’s disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Ionis Pharmaceuticals, Inc</p>
<p>*Option to acquire exclusive license from Ionis Pharmaceuticals.</p>
<p>Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders.</p>
<p>&nbsp;</p>
<p><b>How this investigational therapy could help:</b><i></i></p>
<p>Research indicates that genetic factors contribute to the complex pathogenesis of Parkinson’s disease, including mutations in the LRRK2 gene. BIIB094 is an antisense oligonucleotide (ASO) designed to bind to LRRK2 mRNA and mediate its degradation, reducing LRRK2 protein levels and potentially slowing disease progression.&nbsp;</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT03976349?term=BIIB094&amp;draw=1&amp;rank=1" target="_blank">Learn more about the BIIB094 clinical trial.</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB100" class="product-pipeline__products--product phase1 therapy-area:amyotrophic-lateral-sclerosis">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB100 (XPO1 inhibitor)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Amyotrophic lateral sclerosis (ALS)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.</p>
<p>How this investigational therapy could help:<i></i></p>
<p>BIIB100 is an inhibitor of Exportin 1 (XPO1), a protein that mediates export of many proteins and RNA species from the cell nucleus. Dysfunction in nucleocytoplasmic transport (the process by which proteins and RNA molecules move in and out of the nucleus) appears to play a role in ALS and other neurodegenerative diseases.</p>
<p>BIIB100 is being evaluated to see if it can slow the progression of sporadic ALS by normalizing the nuclear traffic of proteins and RNA.</p>
<p><a></a><a href="https://www.clinicaltrials.gov/ct2/show/NCT03945279?term=biib100&amp;rank=1" target="_blank">Learn more about the BIIB100 clinical trial.</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB101" class="product-pipeline__products--product phase1 therapy-area:multiple-system-atrophy">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p>BIIB101 (SNCA ASO)</p>
 </div>
                                        <div class="product__info-disease"><p>Multiple System Atrophy (MSA)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Ionis Pharmaceuticals, Inc</p>
<p>*Option to acquire exclusive license from Ionis Pharmaceuticals.</p>
<p>Multiple system atrophy (MSA) is a rare, rapidly progressive, ultimately fatal disorder of the central nervous system. Symptoms typically develop in adulthood, usually around 50-60 years old. Motor symptoms of the disease can include slow movement, muscle stiffness, poor muscle coordination and balance. Autonomic symptoms can include low blood pressure, loss of bladder or bowel control, sleep and psychiatric problems.</p>
<p><b>How this investigational therapy could help:</b><i></i></p>
<p>Research indicates that accumulation of alpha-synuclein (SNCA) within the central nervous system leads to neuronal degeneration and loss of neurologic function. BIIB101 is an antisense oligonucleotide (ASO) designed to bind to SNCA mRNA and mediate its degradation, which may reduce SNCA protein levels and potentially slow disease progression.&nbsp;</p>
<p>Learn more about BIIB101 clinical trial at <a href="https://www.clinicaltrials.gov/ct2/show/NCT04165486?term=biib101&amp;draw=2&amp;rank=1">https://www.clinicaltrials.gov/ct2/show/NCT04165486?term=biib101&amp;draw=2&amp;rank=1</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB105" class="product-pipeline__products--product phase1 therapy-area:amyotrophic-lateral-sclerosis">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB105 (ATXN2 ASO)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Amyotrophic lateral sclerosis (ALS)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Ionis Pharmaceuticals, Inc</p>
<p>*Option to acquire exclusive license from Ionis Pharmaceuticals.</p>
<p>ALS is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>Preclinical research indicates that Ataxin-2 (ATXN2) is an important modulator of TDP-43 pathology, the key pathology in about 95 percent of ALS cases. Preclinical studies have shown that increasing ATXN2 exacerbates (worsens) TDP-43-mediated death of motor neurons, while decreasing ATXN2 mitigates this toxicity, which may improve functionality and potentially increase survival. BIIB105 is an antisense oligonucleotide (ASO) designed to bind to ATXN2 mRNA and mediate its degradation, which is expected to reduce ATXN2 protein levels and potentially slow disease progression for the broad ALS population.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB107" class="product-pipeline__products--product phase1 therapy-area:multiple-sclerosis">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB107 (anti-VLA4)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Multiple Sclerosis</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.</p>
<p><b>Why we believe this investigational drug has the potential to help:</b></p>
<p>BIIB107 is a humanized monoclonal antibody that targets α4 integrins, which are essential for leukocyte trafficking into the brain and are an important element in pathology of MS. It’s hypothesized that BIIB107, by disrupting the interaction of α4 integrin and its ligands and therefore preventing leukocyte trafficking into the brain, has the potential to reduce inflammation and provide therapeutic benefit in MS.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT04593121">Learn more about the BIIB107 clinical trial.</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB118" class="product-pipeline__products--product phase1 therapy-area:parkinsons-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB118 (CK1 inhibitor)</b></p>
 </div>
                                        <div class="product__info-disease"><p>&nbsp;Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s Disease (PD)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>BIIB118 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases. Biogen plans to develop the Phase 1 asset for the treatment of ISWRD in PD.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT02691702?term=b8001002&amp;draw=2&amp;rank=1">Learn more about BIIB118 clinical trial</a>.</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB121" class="product-pipeline__products--product phase1 therapy-area:angelman-syndrome">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB121 (UBE3A ASO)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Angelman Syndrome</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Ionis Pharmaceuticals, Inc</p>
<p>*Option to acquire exclusive license from Ionis Pharmaceuticals.</p>
<p>Angelman syndrome is a rare neurodevelopmental order that begins between 6 and 12 months of age and causes delayed motor milestones, muscular weakness and potentially speech daily. Patients need constant care as the disease progresses and are unable to live independently.</p>
<p>Why we believe this investigational drug has the potential to help:</p>
<p>Angelman syndrome is caused by deficient expression and/or function of the UBE3A gene. BIIB121 is designed to restore expression of UBE3A and has the potential to be a first-in-class disease-modifying-therapy for Angelman syndrome.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT05127226">Learn more about the BIIB121 clinical trial.</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB132" class="product-pipeline__products--product phase1 therapy-area:Spinocerebellar-ataxia-type-3">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB132 (ATXN-3 ASO)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Spinocerebellar ataxia type 3 (SCA3)</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Ionis Pharmaceuticals, Inc.</p>
<p>*Option to acquire exclusive license from Ionis Pharmaceuticals.</p>
<p>Spinocerebellar ataxia type 3 is a rare monogenetic neurodegenerative disease that results in progressive difficulty with movement that becomes severe, causing significant disability and ultimately, death. Onset is typically in adulthood, with the mean onset at around 30 years of age.</p>
<p>SCA3 is caused by mutations in the ataxin-3 gene, leading to a toxic gain-of-function that results in cell death in the brainstem and cerebellum. BIIB132 represents a potential first-in-class disease modifying therapy in SCA3.</p>
<p style="text-align: justify;">Why we believe this investigational drug has the potential to help:</p>
<p>BIIB132 aims to suppress ATXN-3 mRNA to reduce expression of the mutant ATXN-3 protein, and potentially slow brainstem and cerebellar atrophy and thus slow deterioration of motor function and coordination.</p>
<p><a href="https://clinicaltrials.gov/ct2/show/NCT05160558">Learn more about the BIIB132 clinical trial.</a></p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            <div class="product-pipeline__products--separator"></div>
                        
                            <li id="BIIB122" class="product-pipeline__products--product phase1 therapy-area:parkinsons-disease">
                                <div class="bio-icon-arrow-thin-down"></div>
                                <div class="product__info">
                                    <div class="product__info-text-wrapper">
                                        <div class="product__info-name"><p><b>BIIB122 (DNL151)</b></p>
 </div>
                                        <div class="product__info-disease"><p>Parkinson’s disease</p>
</div>
                                        <div class="product__info-moreInfo">
                                            <div class="product__moreInfo-description"><p>Collaboration with Denali Therapeutics, Inc.</p>
<p>Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders.</p>
<p><b>How this investigational therapy could help:</b></p>
<p>Preclinical research indicates that genetic factors may contribute to the complex pathogenesis of Parkinson’s disease, including mutations in the LRRK2 gene. BIIB122 is a selective and brain-penetrant small molecular inhibitor of LRRK2, that may reduce lysosomal dysfunction and potentially slow disease progression.&nbsp;</p>
</div>
                                        </div>
                                    </div>
                                    <div class="product__info-phases">
                                        <div class="product__info-phase product__info-phases-one"></div>
                                        <div class="product__info-phase product__info-phases-two"></div>
                                        <div class="product__info-phase product__info-phases-three"></div>
                                        <div class="product__info-phase product__info-phases-filing"></div>
                                    </div>
                                </div>
                            </li>
                            
                        
                    </ul>
                    <div class="product-pipeline__filtersLegend">
                        Currently no results for this search
                    </div>
                </div>
            </div>
        </div>
    </div>

    




<style>
    .product__info-name p{
        display: inline;
    }
    .product-pipeline__filterby--space{
      display:block;
      margin:30px 0 0;
    }
</style></div>
<div class="columncontrol section">






<div class="column-control-527dd165 row">
	
	
	
	
		<div class="col col-xs-12 col-sm-4 col-md-4">
			<div class="column-control-column">
				<div class="text parbase section">

<link rel="stylesheet" href="/etc.clientlibs/wcm/foundation/clientlibs/accessibility.min.6fe5d4427361a4c0ca5a75457e3e4256.css" type="text/css">


    <h4><span style="white-space: pre;">	</span>&nbsp;&nbsp;&nbsp;&nbsp;Last updated: June 1, 2022.</h4>

</div>


			</div>
		</div>
		<div class="col col-xs-12 col-sm-4 col-md-4">
			<div class="column-control-column">
				

			</div>
		</div>
		<div class="col col-xs-12 col-sm-4 col-md-4">
			<div class="column-control-column">
				

			</div>
		</div>
	
	
	
	
		
</div>
</div>


		
		
		</div>
		
		
		

<div>


    



<script>
        var altlist = [];
</script>



    <div id="exit-site" class="exit-site modal fade" role="dialog" aria-hidden="true" tab-index="-1">
    	<div class="modal-dialog modal-wide">
    		<div class="modal-content content">
    			<div class="modal-header">
                	<button role="button" class="close" data-dismiss="modal">
                    	<span aria-hidden="true">×</span>
                        <div></div>
                    </button> 
    			</div>
    			<div class="modal-body underline">
      				<div id="exit-site-modal-text" class="modal-title" style="display: none;"><h2>Important Notice:</h2>
<p>You are now leaving Biogen’s corporate website.<br>
We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from Biogen’s standards.</p>
<p><i>Third Party Sites</i><br>
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.</p>
<p>Thank you for visiting our site.</p>
<p>&nbsp;</p>
</div>
                    <div id="exit-site-modal-alt-text" class="modal-title" style="display: none;"></div>
    				<div class="modal-buttons text-center">
            			<a href="#" class="cancel" data-dismiss="modal">Cancel</a>
           		    	<a href="" target="_blank" id="continue-button" class="btn bio-btn">
                			<span class="btn-cta-text">Continue</span>
            			</a>
    				</div>
    			</div><!-- /.modal-body underline -->
    		</div>
    	</div>
    </div>


<!-- BEGIN FOOTER -->
<footer class="footer">
    <div class="inner">
        <div class="row">
            <div class="col-md-9 col-sm-12">
                <div class="footer-list footer-list-mod">
                    <ul class="list list-divider">
                        <li class="list-item">
                            <a href="http://investors.biogen.com/" class="list-link" target="_blank">Investors</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/careers.html" class="list-link">Careers</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="http://investors.biogen.com/news" class="list-link" target="_blank">News Releases</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/stories.html" class="list-link">Our Stories</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/newsletter-signup.html" class="list-link">Receive Our Updates</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/contact.html" class="list-link">Contact Us</a>
                        </li>
                    </ul>
                </div>
            </div>

            <!-- SOCIAL ICONS -->
            <div class="col-md-3 col-sm-4 col-8">
                <div class="soc footer-soc">
                    <div class="soc-text">Follow us:</div>
                    <ul class="soc-list">
                        <li class="soc-list-item">
                            <a href="https://twitter.com/biogen" target="_blank" class="footer-social__link bio-icon-twitter">
										
										
                            </a>

                        </li>
                    
                        <li class="soc-list-item">
                            <a href="https://youtube.com/biogen" target="_blank" class="footer-social__link bio-icon-youtube">
										
										
                            </a>

                        </li>
                    
                        <li class="soc-list-item">
                            <a href="https://www.linkedin.com/company/biogen-/" target="_blank" class="footer-social__link bio-icon-linkedin">
										
										
                            </a>

                        </li>
                    
                        <li class="soc-list-item">
                            <a href="https://www.facebook.com/Biogen/" target="_blank" class="footer-social__link icons-facebook-grey">
										
										
                            </a>

                        </li>
                    </ul>
                </div>
            </div>
        </div>

        <!--SUB FOOTER -->
        <div class="row">
            <div class="col-md-12 col-sm-12">
                <div class="footer-list">
                    <ul class="list list-small">
                        <li class="list-item">
                            <a href="/en_us/terms-and-conditions.html" class="list-link">Terms &amp; Conditions</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/privacy-policy.html" class="list-link">Privacy Policy</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/california-policy.html" class="list-link">Notice to CA Residents </a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/privacy-policy.html#cookiepolicy" class="list-link">Cookie Policy</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/forward-looking-statements.html" class="list-link">Forward-Looking Statement</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="/en_us/community-guidelines.html" class="list-link">Community Guidelines</a>
                        </li>
                    
                        <li class="list-item">
                            <a href="http://#" class="list-link">© 2021 Biogen</a>
                        </li>
                    </ul>
                </div>
            </div>
        </div>
    </div>
</footer>
</div>




<div id="open-modal" class="open-modal modal fade" role="dialog" aria-hidden="true" tab-index="-1">
    <div class="modal-dialog modal-wide">
        <div class="modal-content content">
        </div>
    </div>

</div>




        <div class="body-overlay"></div>
<div class="scroll-indicator" style="display: block;">
</div>  



		<div>







<!--
More detailed timing info is available by uncommenting some code in the timing.jsp component
Timing chart URL:
http://chart.apis.google.com/chart?chtt=pipeline.html+%28456081ms%29&cht=bhs&chxt=x&chco=c6d9fd,4d89f9&chbh=a&chds=0,456081,0,456081&chxr=0,0,456081&chd=t:6,10475,10675,58453,66914,215755,368107,370516,373488,375367,393127,395179,396947,399576,437471,444761,447467|1629,602,395,346,253680,3549,200,939,65243,15761,45196,2802,483,186,281,461,8614&chly=handleSecurity|headlibs.jsp|dtm_include.jsp|clientcontext.jsp|primaryheader.html|searchpod.html|orphannav.html|masthead.html|parsys.jsp|pipelinecomponent.html|columncontrol.html|parsys.jsp|text.jsp|parsys.jsp|parsys.jsp|exit.html|footer.html&chs=600x500
-->

</div>
		
        


    
<script src="/etc/designs/dxp/corp/clientlib.min.js"></script>






        
            <script type="text/javascript" src="/content/dam/corporate/en_us/scripts/storyvideoclick.js"></script>
        
            <script type="text/javascript" src="/content/dam/corporate/en_us/scripts/redirect-globalsites.js"></script>
        
		<div><script type="text/javascript">_satellite.pageBottom();</script><script src="//rum-static.pingdom.net/pa-5513f45aabe53dcf0afb801d.js" async=""></script>
</div>

<script>
    var cards = "";

    var card = $('*[data-card-name]');


    card.each(function(index){
        var pos = "pos-" + (index - 1);

        if(index < 2){
            pos = "pos-0";
        }
        
        if(index != 0){
            cards+=";";
            if(index == card.length - 1){
                pos = "pos-footer"
            }
        }

        var $this = $(this);
        var name = $.trim($this.attr('data-card-name'));
        $this.attr('data-card-pos', pos);
        $this.attr('data-card-name',name);

        cards += name + ":" + pos;

    });

    populate.values['cards'] = cards;

</script>

<span data-tracking="populate"></span>



	
    
<script src="/etc.clientlibs/cq/analytics/clientlibs/sitecatalyst/util.min.js"></script>



	
    
<script src="/etc.clientlibs/cq/personalization/clientlib/personalization/integrations/commons.min.js"></script>
<script src="/etc.clientlibs/cq/analytics/clientlibs/sitecatalyst/tracking.min.js"></script>





<script>
	CQ_Analytics.EventDataMgr.data = populate.values
</script>
	
<div id="overlayVideo-replace"></div></body></html>